Skip to main content
Aquestive Therapeutics, Inc. logo

Aquestive Therapeutics, Inc. — Investor Relations & Filings

Ticker · AQST ISIN · US03843E1047 US Manufacturing
Open in API
Filings indexed 607 across all filing types
Latest filing 2018-07-20 Regulatory Filings
Country US United States of America
Listing US AQST

About Aquestive Therapeutics, Inc.

https://aquestive.com/

Aquestive Therapeutics is a pharmaceutical company that develops and commercializes medicines using its proprietary PharmFilm® technology. This oral film drug delivery system provides a non-invasive and convenient alternative to conventional therapies, such as injections, by enabling the oral administration of complex molecules. The company's development pipeline is focused on addressing unmet medical needs in central nervous system (CNS) disorders and severe allergic reactions. Key product candidates include Anaphylm™, an epinephrine sublingual film for the emergency treatment of anaphylaxis, and Libervant®, a diazepam buccal film for the management of seizure clusters.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2018
Regulatory Filings Classification · 100% confidence The document is a letter from a company (Aquestive Therapeutics, Inc.) responding to comments from the SEC Division of Corporation Finance staff regarding an Amendment No. 1 to a Registration Statement on Form S-1. The letter discusses specific comments on stockholder disclosures and accounting treatments related to a corporate conversion and stock split. The document references the Registration Statement on Form S-1 and amendments thereto, which are filings related to securities registration, not financial reports or earnings releases. The document is a correspondence letter addressing regulatory comments and amendments to a registration filing, not a report or announcement of financial results or corporate governance changes. It is a regulatory filing correspondence responding to SEC comments on a registration statement. The document length is short (3283 characters), and it is clearly a regulatory communication rather than a report or announcement. Therefore, the appropriate classification is Regulatory Filings (RNS).
2018-07-20 English
S-1/A
Capital/Financing Update Classification · 95% confidence The document is a Form S-1/A, which is a registration statement filed with the U.S. Securities and Exchange Commission (SEC) under the Securities Act of 1933. It is used by companies planning an initial public offering (IPO) to register their securities. The text includes details about the offering, underwriting, risk factors, management discussion, and financial data, typical of a prospectus for a public offering. This type of filing is related to capital raising activities and financing updates rather than annual reports, earnings releases, or other categories. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief summary, supporting a high confidence level.
2018-07-20 English
Regulatory Filings 2018
Regulatory Filings
2018-07-19 English
S-1/A
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A Registration Statement filed with the U.S. Securities and Exchange Commission (SEC) for Aquestive Therapeutics, Inc. It is a pre-effective amendment to a registration statement under the Securities Act of 1933, related to an initial public offering (IPO) of common stock. The document includes detailed information about the offering, company overview, risk factors, management discussion, financial data, and underwriting details. This type of filing is a capital markets document used to register securities for public sale and is not an annual report, earnings release, or other financial report. It is specifically a registration statement amendment related to capital raising activities.
2018-07-16 English
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC Division of Corporation Finance regarding a Registration Statement on Form S-1. It discusses a re-evaluation of a fair value determination related to compensation expense and references an amendment to the Registration Statement on Form S-1. The content is correspondence about the filing and valuation adjustments, not the filing itself or a financial report. The document length is short (2975 characters) and it is a communication or regulatory correspondence rather than a report or announcement of results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory correspondence and filings that do not fit other categories.
2018-07-12 English
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC staff regarding a Registration Statement on Form S-1 for Aquestive Therapeutics, Inc. It discusses valuation analysis related to shares issued upon termination of performance unit plans and references the Form S-1 filing. The content is correspondence providing additional analysis and clarifications to the SEC, not the actual registration statement or financial report itself. The document length is 7477 characters, which is relatively short and the text is a letter rather than a full report. It does not contain financial statements or substantive financial data but rather explanations and responses to SEC inquiries. Therefore, this document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings and correspondence that do not fit other specific categories.
2018-07-11 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.